A cardiologist by training, Dr. Every has been with Frazier Healthcare Partners since 1999. He has led or co-led exited investments including Biostent (acquired by Abbott), Calibra Medical (acquired by LifeSpan), Rigel Pharmaceuticals (NASDAQ: RIGL), Flowcardia (acquired by C.R. Bard), BARRX, (acquired by Covidien), Ascension Orthopedics (acquired by Integra Lifesciences), Zeltiq (NASDAQ: ZLTQ), Glaukos (NASDAQ: GKOS), Packaging Coordinators Inc. (acquired by The Partners Group) and Abode Healthcare (acquired by Tailwind Capital). He currently serves on the boards of Correct Care Solutions, United Derm Partners, Silvergate Pharma, PCI, Leiter’s Compounding Pharmacy, The CORE Institute, and Vein Clinics of America. He also serves on the PRI Investment Committee for the Bill and Melinda Gates Foundation.
Prior to joining Frazier, Dr. Every was an associate professor of medicine and the director of the Cardiovascular Outcomes Research Center (CORC) at the University of Washington.
Nathan earned an M.D. from Emory University School of Medicine and a Masters of Public Health (M.P.H.) from the University of Washington.